3rd Quarter - Report

OGR for PFIZER INC

Firm
OGR
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169). Issues related to COVID-19 response including vaccines and anti-viral therapies; H.R.7007, COVID Supplemental Appropriations Act, 2022. Issues related to the FY2023 Appropriations Process. Issues related to drug supply chain; H.R.3927/S.2082, MADE in America Act. Issues related to PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). 340B drug discount program policy issues. Antimicrobial Resistance; H.R.3932, PASTEUR Act.

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 4348 (117th), S. 2082 (117th), H.R. 3927 (117th), H.R. 5376 (117th), H.R. 7667 (117th), H.R. 7007 (117th), H.R. 3932 (117th), H.R. 6833 (117th)

Medicare/Medicaid MMM

Medicare Part D Program; S.912/H.R.1978, Protecting Seniors Through Immunization Act of 2021.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1978 (117th), S. 912 (117th)

Copyright/Patent/Trademark CPT

Issues related to TRIPS Waiver.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.